Table 5. Clinical trials recently launched to evaluate the antineoplastic profile of mitoxantrone as an off-label medication*.
| Indications | Status | Phase | Notes | Ref. |
|---|---|---|---|---|
| MDS |
Not yet recruiting |
I/II |
Combined with araC, decitabine and etoposide |
NCT01729845 |
| Recruiting |
I |
Combined with araC and PD 0332991 |
NCT01701375 |
|
| MCL | Not yet recruiting | II | Combined with dexamethasone, fludarabine and vorinostat | NCT01578343 |
Abbreviations: araC, cytarabine; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome
*
between December 1, 2011, and the day of submission